| Ytd | 23.35% | |
| 1y | 35.40% |
| Open | 247.65 | Prev Close | 247.91 | Low | 247.65 | High | 268.98 | Mkt Cap | 17.25B |
| Vol | 973.38K | Avg Vol | 653.77K | EPS | 12.97 | P/E | 20.28 | Forward P/E | 27.84 |
| Beta | 0.39 | Short Ratio | 6.97 | Inst. Own | 103.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 255.51 | 200-d Avg | 231.27 | 1yr Est | 315.50 |
ASND News
Brent climbed after new U.S.-Iran strikes, pushing the 10-year yield to a 19-month high; Edison and
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and low
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the pri
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the pr
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 poi
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of A
On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pha
BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting Bi
Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a glo
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an ann
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Out
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the p
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raise
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lower
Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annua